Literature DB >> 8513452

Generation of cytotoxic T lymphocytes from peripheral blood of leukaemic patients.

A M Nouri1, E Dorey, C L Davis, A Rohatiner, T A Lister, R T Oliver.   

Abstract

Peripheral blood mononuclear cells from 13 patients with acute leukaemia were used to establish long-term interleukin-2-dependent cytotoxic T lymphocytes. Cells were grown in RPMI medium containing interleukin-2 (IL-2, 100 U/ml) and 2.5% conditioned medium prepared by activating normal lymphocytes with phytohaemagglutinin. Proliferation of IL-2-dependent CD3-positive lymphocytes was seen in 1 of 2 acute lymphocytic leukaemia cases (ALL), 1 of 4 acute myelogenous leukaemia cases (AML) (M1) and 8 of 8 more differentiated AML. In 2 cases with detectable leukaemic cell markers (1 ALL and 1 AML) passageable cells were developed, that expressed normal T cell phenotypes (namely CD3, CD4 and CD8) at the expense of leukaemic cells. In 1 of 2 cases, long-term IL-2-cultured cells showed specific cytotoxic activity against autologous leukemic cells. The percentage killing against autologous and two allogeneic target cell lines at a 50/1 effector/target (E/T) ratio was 42%, 9% and 19% respectively. Similarly the cytotoxic activity of IL-2 activated from 4 different individuals against conventional tumour targets K562 and Daudi at a ratio of 50/1 was 29%-68% (median = 55%) and 34%-78% (median = 61%) respectively. It was also found that this killing potential of the activated cells was maintained for as long as culture was continued (median 23 days, range 17-75 days). The mechanism(s) of T cell proliferation at the expense of leukaemic blast cells in the case of a minority of leukaemic patients and the possible clinical therapeutic potential of these cells following in vitro IL-2 activation deserve further investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513452     DOI: 10.1007/BF01516941

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  AN IMMUNE REACTION IN MAN AGAINST SEMINOMAS, DYSGERMINOMAS, PINEALOMAS, AND THE MEDIASTINAL TUMOURS OF SIMILAR HISTOLOGICAL APPEARANCE?

Authors:  A H MARSHALL; A D DAYAN
Journal:  Lancet       Date:  1964-11-21       Impact factor: 79.321

2.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

4.  Immunohistochemical detection of tissue-infiltrating lymphocytes in bladder tumors.

Authors:  H Tsujihashi; S Uejima; T Akiyama; T Kurita
Journal:  Urol Int       Date:  1989       Impact factor: 2.089

5.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

6.  Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer.

Authors:  F Momburg; T Degener; E Bacchus; G Moldenhauer; G J Hämmerling; P Möller
Journal:  Int J Cancer       Date:  1986-02-15       Impact factor: 7.396

7.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

8.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

9.  Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.

Authors:  S K Lee; R T Oliver
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.